Klingman D, Bielory L, Wang Y, Silverman S, Bell C F, Joy K A, Dever M T, Jones D A
PAREXEL International, Alexandria, Virginia, USA.
Manag Care Interface. 2001 Feb;14(2):62-6.
A new class of asthma drugs modifying the leukotriene pathway was introduced in 1996. The authors investigated outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast. The study group included patients with asthma (12-64 yr), most with mild-to-moderate, persistent asthma, who had at least two zafirlukast prescriptions within 90 days after the start of zafirlukast treatment. Zafirlukast treatment was associated with reductions in occurrence of outpatient visits, emergency department visits, inpatient stays, and prescriptions for short-acting beta-adrenergic agonists in the next six months (all P < .05). A 12-month pre- and post-zafirlukast treatment comparison in a smaller group of patients and a classification of patients into three mutually exclusive outcome groups (increase, decrease, or no change in outcome events) verified the majority of the findings. A cost analysis from a third-party perspective indicated that costs of zafirlukast treatment were more than offset by cost savings associated with the reductions in outcome events.
1996年引入了一类新型的、作用于白三烯途径的哮喘药物。作者研究了使用白三烯受体拮抗剂扎鲁司特相关的结局变化。研究组包括哮喘患者（12至64岁），大多数为轻至中度持续性哮喘患者，他们在扎鲁司特治疗开始后90天内至少有两张扎鲁司特处方。扎鲁司特治疗与接下来六个月内门诊就诊、急诊就诊、住院天数以及短效β-肾上腺素能激动剂处方的减少相关（所有P < 0.05）。在一小部分患者中进行的扎鲁司特治疗前后12个月的比较，以及将患者分为三个相互排斥的结局组（结局事件增加、减少或无变化），证实了大多数研究结果。从第三方角度进行的成本分析表明，扎鲁司特治疗的成本被与结局事件减少相关的成本节省所抵消。
